

# GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]

4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil  
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



Date: 14<sup>th</sup> August, 2023

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai-400001  
Email ID: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

**Ref: Genomic Valley Biotech Limited (539206/ GVBL)**

**Sub: Outcomes of Board Meeting and Un-Audited Financial Results (Standalone) for the Quarter and Three Months ended 30<sup>th</sup> June, 2023**

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Un-Audited Financial Results (Standalone) for the Quarter and Three Months ended 30<sup>th</sup> June, 2023 of the Company as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.

The above information will also be available on the Company's Website, [www.genomicvalley.com](http://www.genomicvalley.com).

The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 04:30 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Anupam Aditya  
Company Secretary & Compliance Officer  
M. No.: A60613

**GENOMIC VALLEY BIOTECH LIMITED**

Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,

TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

Statement of Un-Audited Financial Results for the quarter ended 30/06/2023 and Year to date from 01/04/2023 to 30/06/2023

Part I

In Rs.

Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous year ended
		30-Jun-23 Un-Audited	31-Mar-23 Audited	30-Jun-22 Un-Audited	31-Mar-23 Audited
I	Revenue From Operations	585,500	9,960,750	10,338,000	27,225,190
II	Other Income	15,002	120,576	144,877	425,453
III	<b>Total Revenue (I+II)</b>	<b>600,502</b>	<b>10,081,326</b>	<b>10,482,877</b>	<b>27,650,643</b>
IV	<b>Expenses</b>				
	Cost of materials consumed	-	-	-	-
	Purchases of Stock-in-Trade	-	-	9,817,600	15,836,800
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-
	Employee benefits expense	195,000	337,590	825,487	1,496,087
	Financial costs	-	-	-	-
	Depreciation and amortization expense	2,731	-73,405	76,324	79,243
	Other expenses	134,666	300,120	275,549	1,106,730
	<b>Total Expenses (IV)</b>	<b>332,397</b>	<b>564,305</b>	<b>10,994,960</b>	<b>18,518,860</b>
V	<b>Profit / (Loss) before exceptional item and tax (III-IV)</b>	<b>268,105</b>	<b>9,517,021</b>	<b>-512,083</b>	<b>9,131,783</b>
VI	Exceptional Item	-	285,048	5,104,788	2,643,164
VII	<b>Profit/loss before Tax (V-VI)</b>	<b>268,105</b>	<b>9,802,069</b>	<b>4,592,705</b>	<b>6,488,619</b>
VIII	<b>Tax expenses</b>				
	(1) Current Tax	-	-	-	-
	(2) Deferred Tax	-	6,080	-	6,080
IX	<b>Profit/ (Loss) for the period from continuing operations (VII-VIII)</b>	<b>268,105</b>	<b>9,795,989</b>	<b>4,592,705</b>	<b>6,482,539</b>
X	Profit/ (Loss) from discontinued operations	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-
XIII	<b>Profit/Loss for the period (IX+XII)</b>	<b>268,105</b>	<b>9,795,989</b>	<b>4,592,705</b>	<b>6,482,539</b>

*Kamran*



XIV	Other Comprehensive Income				-
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	268,105	9,795,989	4,592,705	6,482,539
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):				
	1) Basic	0.09	3.21	1.50	2.12
	2) Diluted	0.09	3.21	1.50	2.12
XVIII	Earning Per Equity Share (for discontinued operation):				
	1) Basic	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):				
	1) Basic	0.09	3.21	1.50	2.12
	2) Diluted	0.09	3.21	1.50	2.12

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 14th August, 2023. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Comapnies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited



*Yogesh Agrawal*

Yogesh Agrawal  
(Managing Director)  
DIN-01165288

Add: G-74 Pushkar Enclave  
Paschim Vihar, New Delhi-110063

Place : Delhi  
Dated : 14.08.2023



**ANDROS & CO.**  
**CHARTERED ACCOUNTANTS**

901, TOWER-1, PEARL OMAXE, PLOT B-1,  
NETAJI SHUBHASH PLACE, PITAMPURA  
DELHI-110034  
Ph-011-47060901  
Email: cabhavukgarg@gmail.com

**LIMITED REVIEW REPORT**

To,  
The Board of Directors of  
Genomic Valley Biotech Limited,  
4 K.M. Stone, Berri Chharra Road,  
Village- Kherka Musalman, P.O. Tandaheri,  
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter ended on  
June 30, 2023 and year to date from April 01, 2023 to June 30, 2023**

We have reviewed the accompanying statement of unaudited financial results for the **Quarter ended on June 30, 2023 and year to date from April 01, 2023 to June 30, 2023** ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.


This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ANDROS & CO.  
Chartered Accountants



(CA Bhavuk Garg)  
(Partnership Firm)  
(Membership No.-502310)

Place: Delhi  
Date: 14-08-2023

UDIN: 23502310-BGUYKF-8807

Peer Review: 01211